Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Core Insights - Lipella Pharmaceuticals Inc. has been granted U.S. Patent No. 12,326,492 for a method to detect interstitial cystitis using MRI, providing protection until at least 2045 [1][2] - The patented method aims to enhance outcome assessments for mucosal disorders, including existing programs for oral lichen planus, hemorrhagic cystitis, and bladder cancer [2] - The patent strengthens Lipella's strategic position in drug delivery, allowing non-invasive monitoring of body cavity lesions, which could serve as an early detection tool [3] Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications [3] - The company targets diseases with significant unmet needs where no approved drug therapies currently exist [3] - Lipella completed its initial public offering in 2022 [3]